The Position of Pranlukast, a Cysteinyl Leukotriene Receptor Antagonist, in the Long-Term Treatment of Asthma

Obase, Yasushi; Shimoda, Terufumi; Matsuse, Hiroto; Kondo, Yuki; Machida, Ikuko; Kawano, Tetsuya; Saeki, Sachiko; Tomari, Shinya; Mitsuta-Izaki, Kazuko; Matsuo, Nobutake; Kohno, Shigeru

doi:10.1159/000077419

Cited by 12 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies have also supported the use of long-acting β 2 agonists and ICS together [6, 7, 8, 9, 10, 11]. An alternative approach is to add a leukotriene receptor antagonist to an ICS [12, 13]. Montelukast is a leukotriene receptor antagonist that improves asthmatic inflammation and prevents bronchoconstriction [14, 15, 16].…”

Section: Introductionmentioning

confidence: 99%

Addition of Formoterol or Montelukast to Low-Dose Budesonide: An Efficacy Comparison in Short- and Long-Term Asthma Control

Ceylan

Gençer²,

Aksoy³

2004

Respiration

View full text Add to dashboard Cite

Background: Asthma is a chronic inflammatory disease of the airways. Inhaled corticosteroids are very important in anti-inflammatory treatment, but to a great extent they cannot control asthma alone. In addition to corticosteroids, long-acting β₂ agonists and leukotriene antagonists are used for asthma control. Objective: In this study, the effect of the addition of formoterol and montelukast on asthma control in patients with moderately persistent asthma who were symptomatic while using a low dose of inhaled budesonide was compared. Methods: At the beginning of the study, 40 symptomatic patients with moderately persistent asthma used 400 µg/day budesonide for a 4-week training period, and were then divided randomly into two groups, each composed of 20 persons. For the first group’s treatment regime, inhaled formoterol (9 µg) twice a day was added, and for the second group’s treatment regime, one-dose oral montelukast (10 µg) was added. These patients were followed up for 8 weeks. The patients’ peak expiratory flow (PEF) values measured in the morning and at night, changes in PEF, forced expiratory volume in 1 s, asthma symptom score and the symptom-relieving therapy used during the 12-week study period were recorded and evaluated in the clinic at the very beginning and at the end of each period. Results: Before the study, the morning PEF value of the group for whom formoterol was added to budesonide (FB) was 266.3 ± 59.3 liters/min, and in the group for whom montelukast was added to budesonide (MB), it was 262.8 ± 53.8 liters/min (p > 0.05). After the 8-week treatment period, the morning PEF values were found to be 320.5 ± 54.4 liters/min in the FB group and 293.3 ± 52.4 liters/min in the MB group; at the end of the study, it was seen that although there was an increase in morning PEF of 54.2 ± 15.2 liters/min in the FB group, there was an increase of only 30.5 ± 25.3 liters/min in the MB group (p < 0.0001). Before the study, night PEF values were 287 ± 56.6 liters/min in the FB group and 283 ± 48.5 liters/min in the MB group (p > 0.05). At the end of the treatment, the night PEF values were found to be 331.5 ± 56.1 liters/min in the FB group and 310 ± 53.1 liters/min in the MB group. At the end of the study, it was observed that although there was an increase in night PEF of 44.5 ± 23.3 liters/min in the FB group, there was an increase of only 27 ± 24.1 liters/min in the MB group (p < 0.001). Although asthma symptom scores and the use of symptom-relieving drugs showed similarities between the two groups at the beginning of the study, after treatment, the FB group had better results than the MB group with respect to these two parameters (p < 0.0001 for both). It was also seen that the two treatments are tolerated equally well. Conclusion: FB treatment, which causes a considerable improvement in lung function, showed better asthma control than MB treatment in patients with moderately persistent asthma.

show abstract

Section: Introductionmentioning

confidence: 99%

Addition of Formoterol or Montelukast to Low-Dose Budesonide: An Efficacy Comparison in Short- and Long-Term Asthma Control

Ceylan

Gençer²,

Aksoy³

2004

Respiration

View full text Add to dashboard Cite

show abstract

“…A long-term follow-up study has confirmed the safety of LTRAs as well as the absence of the tachyphylaxis induced by β2-agonists [94].…”

Section: Safetymentioning

confidence: 71%

Leukotriene receptor antagonists pranlukast and montelukast for treating asthma

Matsuse

Kohno

2013

Expert Opinion on Pharmacotherapy

Self Cite

View full text Add to dashboard Cite

IntroductionThe prevalence of bronchial asthma, which is a chronic inflammatory disorder of the airway, is increasing worldwide. Although inhaled corticosteroids (ICS) play a central role in the treatment of asthma, they cannot achieve good control for all asthmatics and medications such as leukotriene receptor antagonists (LTRAs) with bronchodilatory and anti-inflammatory effects often serve as alternatives or add-on drugs. Several issues such as predicted responses, effects of peripheral airway and airway remodeling and alternative administration routes remain to be clarified before LTRAs PAGE 3 could serve a more effective role in the treatment of asthma. Areas covered

show abstract

“…Although no severe adverse effects were described in their study, long-term use of cimetidine has, in general, adverse side effects, such as inhibition of P450 system, headache, and gynecomastia. In contrast pranlukast has long been used for treating asthma chronically with little adverse effects 20 …”

Section: Discussionmentioning

confidence: 99%

Cysteinyl Leukotriene Receptor Antagonists Inhibit Tumor Metastasis by Inhibiting Capillary Permeability

Nozaki

Yoshikawa

Ishitani³

et al. 2010

Keio J. Med.

View full text Add to dashboard Cite

We explored the possibility of the cysteinyl leukotriene receptor antagonists, pranlukast and montelukast, preventing tumor cell migration through both cerebral and peripheral capillaries. To study tumor cell migration through brain capillaries, male Fisher rats were cannulated via the cisterna magna under pentobarbital anesthesia. RCN9 cells labeled with a fluorescent marker PKH67 were intravenously administered following arachidonic acid administration into the subarachnoid space, and specimens of the central nervous system were collected every 30 min for 8 h. Arachidonic acid increased the fluid volume with elevated white blood cell and RCN9 cell counts. When given 2 h before arachidonic acid administration, pranlukast, but not montelukast, reduced the fluid volume and inhibited white blood cell and RCN9 cell extravasation through the brain capillary. In addition, a Lewis lung carcinoma metastasis model in mice was used to study the inhibitory effect of pranlukast and montelukast against cancer cell extravasation through general capillaries. When mice were given food containing either pranlukast or montelukast, immediately after paw amputation, tumor metastasis was prevented by both drugs, and their survival was prolonged. These results show that pranlukast can inhibit tumor cell migration through both the brain and peripheral capillaries, whereas montelukast inhibits tumor cell migration only in the peripheral capillaries.

show abstract

The Position of Pranlukast, a Cysteinyl Leukotriene Receptor Antagonist, in the Long-Term Treatment of Asthma

Cited by 12 publications

References 33 publications

Addition of Formoterol or Montelukast to Low-Dose Budesonide: An Efficacy Comparison in Short- and Long-Term Asthma Control

Addition of Formoterol or Montelukast to Low-Dose Budesonide: An Efficacy Comparison in Short- and Long-Term Asthma Control

Leukotriene receptor antagonists pranlukast and montelukast for treating asthma

Cysteinyl Leukotriene Receptor Antagonists Inhibit Tumor Metastasis by Inhibiting Capillary Permeability

Contact Info

Product

Resources

About